Mupirocin
Based on 1 publication(s) in Google Scholar
Mupirocin is an antibiotic. Mupirocin inhibits bacterial isoleucyl-tRNA synthetase, blocking protein synthesis. Mupirocin has high activity against Gram-positive bacteria such as Staphylococcus and Streptococcus, as well as some Gram-negative bacteria (such as Haemophilus influenzae). Mupirocin can be used in the research of diseases such as skin infections (such as MRSA infections) and chronic sinusitis.
For research use only. We do not sell to patients.
- Purity: 98.01%
- CAS No.: 12650-69-0
- Formula: C26H44O9
- Molecular Weight:500.62
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
-
Solvent & Solubility
- Purity & Documentation
- References
-
Help & FAQs
-
Covalent Screening Library
HY-L036
-
Antibacterial Compound Library
HY-L049
-
Anti-COVID-19 Compound Library
HY-L052
-
NMPA-Approved Drug Library
HY-L053
-
FDA Approved & Pharmacopeial Drug Library
HY-L066
-
Antibiotics Library
HY-L067
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Microbial Metabolite Library
HY-L084
-
Rare Diseases Drug Library
HY-L102
-
Pediatric Drug Library
HY-L104
-
Anti-Cancer Natural Product Library
HY-L107
-
FDA-Approved Anticancer Drug Library
HY-L122
-
Human Metabolite Library
HY-L123
-
Non-steroidal Anti-Inflammatory Compound Library
HY-L130
-
Heterocyclic Compound Library
HY-L138
-
Off-patent Drug Library
HY-L141
-
Metabolic Enzyme Compound Library
HY-L146
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Covalent Screening Library Plus
HY-L036P
-
Natural Product Library Plus
HY-L021P
-
Drug Repurposing Compound Library Plus
HY-L035P
-
FDA-Approved Drug Library Plus
HY-L022P
-
FDA-Approved Drug Library Mini
HY-L022M
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
Animal Drug Library
HY-L218
-
Natural Product Diversity Scaffold Library
HY-L245
-
Mass Spectrometry Natural Product Library
HY-L262
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Anti-Infection Compound Library
HY-L002
-
Immunology/Inflammation Compound Library
HY-L007
-
Metabolism/Protease Compound Library
HY-L012
-
Natural Product Library
HY-L021
-
FDA-Approved Drug Library
HY-L022
-
Anti-Cancer Compound Library
HY-L025
-
Drug Repurposing Compound Library
HY-L035
Publications Citing Use of MedChemExpress (MCE) Mupirocin
MoreAll Antibiotic Isoforms
More
Biological Activity
Mupirocin inhibits staphylococci and streptococci (except group D streptococci), with a MIC of ≤0.5 μg/mL[1].
Mupirocin (0.1-0.2 mM; 18 h) significantly increases wound closure and proliferation of human keratinocytes (HaCat) and enhances production of growth factors like HGF and PDGF-AA[4].
Mupirocin (≤125 μg/mL) reduces biofilm mass by greater than 90% in all S. aureus isolates[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:Staphylococcus aureus
-
Concentration:0-100 μM/mL
-
Incubation Time:24, 48 hours
-
Result:Resulted in a 90 to 99% reduction at 24 h, with MIC values ranged from 0.12-1.0 μM/mL and MBC values ranged from 4.0-32 μM/mL at 48 h.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c mice (10-12 weeks old) with superficial skin wound infection induced by MRSA USA300[3]
-
Dosage:2%
-
Administration:Topical application to the lesion area, twice daily, for 3 days or 6 days
-
Result:Reduced bacterial loads in the skin lesions by 2.0 log CFU after 3 days of treatment.
Reduced bacterial loads in the skin lesions by 5.1 log CFU after 6 days of treatment.
Chemical Information
-
CAS No. 12650-69-0
-
Appearance Solid
-
Molecular Weight 500.62
-
Formula C26H44O9
-
Color White to off-white
-
SMILES
O[C@@H]1[C@@](CO[C@@H](C/C(C)=C/C(OCCCCCCCCC(O)=O)=O)[C@@H]1O)([H])C[C@H]2[C@@]([C@@H](C)[C@@H](O)C)([H])O2
-
Synonyms
BRL-4910A; Pseudomonic acid
-
Structure Classification
-
Initial Source
Pseudomonas fluorescens
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Microbiol Spectr
Antimicrobial efficacy of Bifidobacterium longum FB1-4 cell-free supernatant against MRSA: insights into mechanisms and food matrix application. [Abstract]2026 Apr 7;14(4):e0099125. PMID: 41769981
Solvent & Solubility
DMSO : ≥ 100 mg/mL (199.75 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (4.99 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (271 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
References
[1]. Sutherland R, et al. Antibacterial activity of mupirocin (pseudomonic acid), a new antibiotic for topical use. Antimicrob Agents Chemother. 1985 Apr;27(4):495-8. [Content Brief]
[2]. Parenti MA, et al. Mupirocin: a topical antibiotic with a unique structure and mechanism of action. Clin Pharm. 1987 Oct;6(10):761-70. [Content Brief]
[3]. Vingsbo Lundberg C, et al. Efficacy of topical and systemic antibiotic treatment of meticillin-resistant Staphylococcus aureus in a murine superficial skin wound infection model. Int J Antimicrob Agents. 2013 Sep. 42(3):272-5. [Content Brief]
[4]. Twilley D, et al. Mupirocin Promotes Wound Healing by Stimulating Growth Factor Production and Proliferation of Human Keratinocytes. Front Pharmacol. 2022 Apr 11;13:862112. [Content Brief]
[5]. Ha KR, et al. In vitro activity of mupirocin on clinical isolates of Staphylococcus aureus and its potential implications in chronic rhinosinusitis. Laryngoscope. 2008 Mar;118(3):535-40. [Content Brief]
[6]. Gilbart J, et al. High-level mupirocin resistance in Staphylococcus aureus: evidence for two distinct isoleucyl-tRNA synthetases. Antimicrob Agents Chemother. 1993 Jan;37(1):32-8. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.9975 mL | 9.9876 mL | 19.9752 mL | 49.9381 mL |
| 5 mM | 0.3995 mL | 1.9975 mL | 3.9950 mL | 9.9876 mL | |
| 10 mM | 0.1998 mL | 0.9988 mL | 1.9975 mL | 4.9938 mL | |
| 15 mM | 0.1332 mL | 0.6658 mL | 1.3317 mL | 3.3292 mL | |
| 20 mM | 0.0999 mL | 0.4994 mL | 0.9988 mL | 2.4969 mL | |
| 25 mM | 0.0799 mL | 0.3995 mL | 0.7990 mL | 1.9975 mL | |
| 30 mM | 0.0666 mL | 0.3329 mL | 0.6658 mL | 1.6646 mL | |
| 40 mM | 0.0499 mL | 0.2497 mL | 0.4994 mL | 1.2485 mL | |
| 50 mM | 0.0400 mL | 0.1998 mL | 0.3995 mL | 0.9988 mL | |
| 60 mM | 0.0333 mL | 0.1665 mL | 0.3329 mL | 0.8323 mL | |
| 80 mM | 0.0250 mL | 0.1248 mL | 0.2497 mL | 0.6242 mL | |
| 100 mM | 0.0200 mL | 0.0999 mL | 0.1998 mL | 0.4994 mL |
Mupirocin Related Classifications
HY-B0958 Related Classifications
Powered by Bioz